Company attributes
Venture Capital Firm attributes
Other attributes
Established in 2019 and based in London, ALSA Ventures is a life science venture capital investment firm with a focus on pharmaceutical and biotechnology companies. The investor specializes in early-stage novel therapeutics.
On the 9th of May 2022, ALSA Ventures and Lonza, a development and manufacturing partner for pharma, biotech, and nutrition industries, reached a collaboration agreement to assist in developing and manufacturing biologics, as well as small molecule drug candidates catering to ALSA’s collection of pre-clinical plus early clinical biotechs.
In October 13, 2020, the investment firm launched Eclipse, a clinical development accelerator with a focus on therapeutics assets that are in late preclinical development. Through the framework, eligible establishments will be chosen for equity investment, as well as funding via the investor's inaugural fund called ALSA Ventures I SCSp. The applications will be analyzed quarterly on a competitive basis, with equity investment that is about $5M provided to awarded companies. After getting the investment, the selected companies will work with ICON, a clinical research organization in order to progress their asset via initial-in-man studies.
